SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Vincerx Pharma Presents Preclinical And Clinical Data On Ptefb/Cdk9 Inhibitor Vip152 In Lymphoma

reuters.com · 06/10/2022 08:10
BRIEF-Vincerx Pharma Presents Preclinical And Clinical Data On Ptefb/Cdk9 Inhibitor Vip152 In Lymphoma

- Vincerx Pharma Inc VINCU:

  • VINCERX PHARMA PRESENTS PRECLINICAL AND CLINICAL DATA ON PTEFB/CDK9 INHIBITOR VIP152 IN LYMPHOMA AT THE EUROPEAN HEMATOLOGY ASSOCIATION 2022 CONGRESS

  • VINCERX - DATA SHOW IMPROVED SELECTIVITY, TARGET MODULATION, EARLY SIGNS OF CLINICAL EFFICACY, CARDIAC SAFETY IN LYMPHOMA PATIENTS TREATED WITH VIP152

Source text for Eikon: ID:nGNX5YQ12V

Further company coverage: VINCU


((reuters.briefs@thomsonreuters.com;))